USP5 inhibits anti-RNA viral innate immunity by deconjugating K48-linked unanchored and K63-linked anchored ubiquitin on IRF3

PLoS Pathog. 2025 Jan 6;21(1):e1012843. doi: 10.1371/journal.ppat.1012843. eCollection 2025 Jan.

Abstract

Interferon regulatory factor 3 (IRF3) is a central hub transcription factor that controls host antiviral innate immunity. The expression and function of IRF3 are tightly regulated by the post-translational modifications. However, it is unknown whether unanchored ubiquitination and deubiquitination of IRF3 involve modulating antiviral innate immunity against RNA viruses. Here, we find that USP5, a deubiquitinase (DUB) regulating unanchored polyubiquitin, is downregulated during host anti-RNA viral innate immunity in a type I interferon (IFN-I) receptor (IFNAR)-dependent manner. USP5 is further identified to inhibit IRF3-triggered antiviral immune responses through its DUB enzyme activity. K48-linked unanchored ubiquitin promotes IRF3-driven transcription of IFN-β and induction of IFN-stimulated genes (ISGs) in a dose-dependent manner. USP5 simultaneously removes both K48-linked unanchored and K63-linked anchored polyubiquitin chains on IRF3. Our study not only provides evidence that unanchored ubiquitin regulates anti-RNA viral innate immunity but also proposes a novel mechanism for DUB-controlled IRF3 activation, suggesting that USP5 is a potential target for the treatment of RNA viral infectious diseases.

MeSH terms

  • Animals
  • HEK293 Cells
  • Humans
  • Immunity, Innate*
  • Interferon Regulatory Factor-3* / immunology
  • Interferon Regulatory Factor-3* / metabolism
  • Mice
  • RNA Virus Infections / immunology
  • RNA Viruses / immunology
  • Ubiquitin / metabolism
  • Ubiquitin-Specific Proteases* / genetics
  • Ubiquitin-Specific Proteases* / immunology
  • Ubiquitin-Specific Proteases* / metabolism
  • Ubiquitination*

Substances

  • Interferon Regulatory Factor-3
  • Ubiquitin-Specific Proteases
  • IRF3 protein, human
  • Ubiquitin

Grants and funding

This work was supported by the National Key Research and Development Program of China (2018YFA0900803 to FM), the National Natural Science Foundation of China (32400726 to FZ, 82301982 to JZ, 32270924 to DL, and 32170880 to FM), the Natural Science Foundation of Jiangsu Province (BK20230281 to JZ, BK20221256 to DL, and BK20200004 to FM), Non-profit Central Research Institute Fund of CAMS (2019PT310028 to FM), the Special Research Fund for Central Universities, Peking Union Medical College (3332024090 to FZ), CAMS Innovation Fund for Medical Sciences (2021-I2M-1-041, 2021-I2M-1-047, 2022-I2M-2-004, and 2022-I2M-2-010 to FM), The Suzhou Municipal Key Laboratory (SZS2023005 to FM), NCTIB Fund for R&D Platform for Cell and Gene Therapy, and 333 High-level Talent Training Project to FM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.